AR045068A1 - Formulacion de liberacion inmediata de composiciones farmaceuticas - Google Patents

Formulacion de liberacion inmediata de composiciones farmaceuticas

Info

Publication number
AR045068A1
AR045068A1 ARP040102583A ARP040102583A AR045068A1 AR 045068 A1 AR045068 A1 AR 045068A1 AR P040102583 A ARP040102583 A AR P040102583A AR P040102583 A ARP040102583 A AR P040102583A AR 045068 A1 AR045068 A1 AR 045068A1
Authority
AR
Argentina
Prior art keywords
formulation
pharmaceutical compositions
immediate release
compositions
pansoprazole
Prior art date
Application number
ARP040102583A
Other languages
English (en)
Inventor
Jeffrey O Phillips
Ken J Widdler
Original Assignee
Univ Missouri
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Missouri filed Critical Univ Missouri
Publication of AR045068A1 publication Critical patent/AR045068A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Composiciones que comprenden un agente neutralizante del pH y un componente de liberación controlada que contiene un agente farmacéutico ácido lábil (omeprazol, pansoprazol y esomeprazol, entre otros). Métodos de uso de dichas composiciones.
ARP040102583A 2003-07-23 2004-07-21 Formulacion de liberacion inmediata de composiciones farmaceuticas AR045068A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US48936303P 2003-07-23 2003-07-23

Publications (1)

Publication Number Publication Date
AR045068A1 true AR045068A1 (es) 2005-10-12

Family

ID=34102857

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040102583A AR045068A1 (es) 2003-07-23 2004-07-21 Formulacion de liberacion inmediata de composiciones farmaceuticas

Country Status (9)

Country Link
US (1) US20050112193A1 (es)
EP (1) EP1660043A4 (es)
JP (1) JP2006528198A (es)
AR (1) AR045068A1 (es)
AU (1) AU2004258984B2 (es)
CA (1) CA2533588A1 (es)
MX (1) MXPA06000873A (es)
TW (1) TW200522981A (es)
WO (1) WO2005009381A2 (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9720061D0 (en) 1997-09-19 1997-11-19 Crosfield Joseph & Sons Metal compounds as phosphate binders
US20050215561A1 (en) * 2004-03-19 2005-09-29 Krishnendu Ghosh Pharmaceutical dosage forms and compositions
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8815916B2 (en) 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
CA2784881C (en) * 2005-02-25 2016-02-09 Takeda Pharmaceutical Company Limited Method for producing granules
WO2006116582A2 (en) * 2005-04-26 2006-11-02 The Curators Of The University Of Missouri Pharmaceutical compositions comprising a substituted benzimidazole, buffering agent and vitamin b12
CA2608505C (en) 2005-05-18 2013-12-24 Da Volterra Colonic delivery of adsorbents
KR101148399B1 (ko) * 2005-06-22 2012-05-23 일양약품주식회사 항궤양제 및 점막보호제를 함유하는 경구용 위장질환치료용 약제 조성물
US20070059342A1 (en) * 2005-09-13 2007-03-15 Johns William C Method and palatable pharmaceutical composition for treating herpes in animals
CA2633254A1 (en) * 2005-12-16 2007-07-05 Tap Pharmaceutical Products, Inc. Pharmaceutical compositions of ilaprazole
EP1965774A2 (en) * 2005-12-30 2008-09-10 Cogentus Pharmaceuticals, Inc. Oral pharmaceutical formulations containing non-steroidal anti-inflammatory drugs and acid inhibitors
US7351853B2 (en) * 2006-01-23 2008-04-01 Albion Advanced Nutrition Method of manufacturing a granular mineral composition
MY157620A (en) 2006-01-31 2016-06-30 Cytochroma Dev Inc A granular material of a solid water-soluble mixed metal compound capable of binding phosphate
US8048413B2 (en) 2006-05-17 2011-11-01 Helene Huguet Site-specific intestinal delivery of adsorbents, alone or in combination with degrading molecules
US20090092658A1 (en) * 2007-10-05 2009-04-09 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
EP2068841B1 (en) * 2006-10-05 2018-09-26 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
US20080103169A1 (en) 2006-10-27 2008-05-01 The Curators Of The University Of Missouri Compositions comprising acid labile proton pump inhibiting agents, at least one other pharmaceutically active agent and methods of using same
US20080166423A1 (en) * 2007-01-06 2008-07-10 Renjit Sundharadas Combination Medication for Treating the Effects of Stomach Acid Reduction Medication on Bone Integrity
GB0714670D0 (en) 2007-07-27 2007-09-05 Ineos Healthcare Ltd Use
GB0720220D0 (en) 2007-10-16 2007-11-28 Ineos Healthcare Ltd Compound
TWI468167B (zh) * 2007-11-16 2015-01-11 威佛（國際）股份有限公司 藥學組成物
EP2252274A4 (en) 2008-02-20 2011-05-11 Univ Missouri COMPOSITION COMPRISING A COMBINATION OF OMEPRAZOLE AND LANSOPRAZOLE, AND A BUFFER AGENT, AND METHODS OF USING THE SAME
WO2009158368A1 (en) * 2008-06-26 2009-12-30 Mcneil-Ppc, Inc. Coated particles containing pharmaceutically active agents
IN2012DN00359A (es) * 2009-07-20 2015-05-22 Vetegen Llc
GB0913525D0 (en) 2009-08-03 2009-09-16 Ineos Healthcare Ltd Method
GB201001779D0 (en) 2010-02-04 2010-03-24 Ineos Healthcare Ltd Composition
EP2364690A1 (en) * 2010-02-12 2011-09-14 Centro De Ingenieria Genetica Y Biotecnologia Orally administrable pharmaceutical pellet of epidermal growth factor
BR112013029199B1 (pt) * 2011-05-13 2022-02-08 Eb Ip Hybritabs B.V. Dispositivo de distribuição de dois fármacos
AU2013305684B2 (en) 2012-08-22 2016-11-24 Xenoport, Inc. Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof
ITMI20121916A1 (it) * 2012-11-09 2014-05-10 Velleja Res Srl Formulati a cessione intra-gastrica ritardata a base di derivati della glycyrrhiza glabra
JP2016509059A (ja) * 2013-02-20 2016-03-24 プレリーフ・インコーポレイテッドＰｒｅｌｉｅｆ Ｉｎｃ． 腸管損傷および密着結合の機能不全に関連する疾患の治療および予防のための方法および組成物
JP2016534133A (ja) 2013-09-06 2016-11-04 ゼノポート，インコーポレイティド （ｎ，ｎ−ジエチルカルバモイル）メチル メチル（２ｅ）ブト−２−エン−１，４−ジオエートの結晶形態、その合成方法及び使用
US11590165B2 (en) * 2014-12-17 2023-02-28 Bausch Health Companies Inc. Formulations of calcium and phosphate for oral inflammation
CN104666268B (zh) * 2015-02-03 2018-10-02 山东省药学科学院 一种埃索美拉唑镁包芯片及其制备方法
EP3288556A4 (en) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
CN105816436B (zh) * 2016-03-22 2019-10-22 广州共禾医药科技有限公司 一种泮托拉唑肠溶微丸、泮托拉唑肠溶缓控释片剂及其制备方法
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
US20200040149A1 (en) * 2016-10-06 2020-02-06 Foundation For Research And Business, Seoul National University Of Science And Technology Polymer-ceramic hybrid film having mechanical properties and elasticity, and method for manufacturing same
KR102080023B1 (ko) 2018-01-29 2020-02-21 주식회사 종근당 에스오메프라졸 및 탄산수소나트륨을 포함하는 안정한 약제학적 조성물
KR102006777B1 (ko) 2018-01-29 2019-10-08 주식회사 종근당 에스오메프라졸 및 탄산수소나트륨을 포함하는 약제학적 제제
US20220288045A1 (en) * 2019-07-26 2022-09-15 Chong Kun Dang Pharmaceutical Corp. Stable Pharmaceutical Composition Comprising Esomeprazole And Sodium Bicarbonate

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
US5026559A (en) * 1989-04-03 1991-06-25 Kinaform Technology, Inc. Sustained-release pharmaceutical preparation
US5167964A (en) * 1992-02-14 1992-12-01 Warner-Lambert Company Semi-enteric drug delivery systems and methods for preparing same
SE9302395D0 (sv) * 1993-07-09 1993-07-09 Ab Astra New pharmaceutical formulation
SE9402431D0 (sv) * 1994-07-08 1994-07-08 Astra Ab New tablet formulation
US5840737A (en) * 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6489346B1 (en) * 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6699885B2 (en) * 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
US6645988B2 (en) * 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
SE9600070D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
US6623759B2 (en) * 1996-06-28 2003-09-23 Astrazeneca Ab Stable drug form for oral administration with benzimidazole derivatives as active ingredient and process for the preparation thereof
DE19626045C2 (de) * 1996-06-28 1998-12-03 Klinge Co Chem Pharm Fab Stabile Arzneiform zur oralen Verabreichung, welche Omeprazol als aktiven Wirkstoff enthält, sowie Verfahren zur Herstellung derselben
AU8354498A (en) * 1997-08-25 1999-03-16 Procter & Gamble Company, The Combined preparations for treating upper gastrointestinal tract distress
US6174548B1 (en) * 1998-08-28 2001-01-16 Andrx Pharmaceuticals, Inc. Omeprazole formulation
SE9803772D0 (sv) * 1998-11-05 1998-11-05 Astra Ab Pharmaceutical formulation
DK1108425T3 (da) * 1999-12-16 2005-09-26 Medinfar Produtos Farmaceutico Nye, stabile flerenhedspræparater, der indeholder substituerede benzimidazoler
HUP0401941A3 (en) * 2001-07-16 2008-04-28 Astrazeneca Ab Pharmaceutical formulation comprising a proton pomp inhibitor and antacids and process for its preparation
SE0203065D0 (sv) * 2002-10-16 2002-10-16 Diabact Ab Gastric acid secretion inhibiting composition

Also Published As

Publication number Publication date
WO2005009381A2 (en) 2005-02-03
AU2004258984A1 (en) 2005-02-03
AU2004258984B2 (en) 2011-02-10
WO2005009381A3 (en) 2005-06-16
CA2533588A1 (en) 2005-02-03
JP2006528198A (ja) 2006-12-14
EP1660043A4 (en) 2012-07-04
US20050112193A1 (en) 2005-05-26
EP1660043A2 (en) 2006-05-31
TW200522981A (en) 2005-07-16
MXPA06000873A (es) 2007-04-09

Similar Documents

Publication Publication Date Title
AR045068A1 (es) Formulacion de liberacion inmediata de composiciones farmaceuticas
ATE382057T1 (de) Stabile formulierung von modifiziertem glp-1
DE602005010788D1 (de) Pharmazeutische Zusammensetzungen zur sicheren Verabreichung von bei der Behandlung von Drogenabhängigkeit verwendeten Arzneimitteln
ATE355065T1 (de) Therapeutische zusammensetzungen bestehend aus antihypotensiva und antiangiogenika
UA88463C2 (ru) Фармацевтическая композиция, которая содержит соединение 1, и процесс лечения вич-инфекции
CL2008002406A1 (es) Composicion de pelicula de disolucion oral que comprende un agente activo cosmetico o farmaceutico, y un copolimero de injerto de poli(alcohol de vinilo)-polietilenglicol (divisional de la solicitud 1825-04).
CL2003002277A1 (es) Composicion farmaceutica inyectable, de deposito de liberacion prolongada, que comprende un agente beneficioso disuelto o disperso en un gel constituido por un polimero bioerosionable y biocompatible; y un solvente.
CA2400317A1 (en) Improved paste formulations
ES2570856T3 (es) Composiciones oftálmicas que contienen una combinación sinérgica de dos polímeros
AR048878A1 (es) Composiciones topicas de metadona y metodos para usarlas
EA200701065A1 (ru) Инъецируемые составы, содержащие нанодисперсный оланзапин
SV2006002174A (es) Composicion de anticuerpo her2
NO20070785L (no) Sammensetninger for levering av svaert vannloselige medikamenter.
BR0114799A (pt) Compostos de ácido cianofenoxi carboxìlico e composições para liberar agentes ativos
PE20060594A1 (es) Composicion farmaceutica que contiene un agonista de ppar
AR045062A1 (es) Formulaciones farmaceuticas para inhibir la secrecion de acido y metodos para preparar y utilizarlas
DE60134245D1 (de) (5-(2-hydroxy-4-chlorbenzoyl)valeriansäure und deren salze, und zusammensetzungen zur zuführung von wirkstoffen, die diese verbindungen enthalten
ATE548034T1 (de) Pharmazeutische zusammensetzungen mit droxidopa
AR039936A1 (es) Formulacion farmaceutica de liberacion modificada
SE0300831D0 (sv) New formulations and use therof
AR045061A1 (es) Formulacion farmaceutica y metodo para tratar trastornos gastrointestinales causados por acido
DK1345595T3 (da) Ionstyrke-uafhængig farmaceutisk formulering med depotfrigivelse
PL402550A1 (pl) Dopochwowe kompozycje farmaceutyczne oraz zastosowanie zródla nadtlenku i bioadhezyjnego nosnika
AR048672A1 (es) Tabletas de desintegracion que comprenden licarbazepina
BRPI0506630A (pt) composição de liberação controlada e método para administrar um medicamento aquoso transmucosal de liberação controlada

Legal Events

Date Code Title Description
FB Suspension of granting procedure